ADAM9在实体肿瘤生物学中的相关研究进展
Research Progress of ADAM9 in the Biology of Solid Tumors
DOI: 10.12677/ACM.2020.1010343, PDF,  被引量   
作者: 朱莉金, 罗 琰, 贾清玉, 陈爱霞, 赵园园*：青岛大学附属医院，山东 青岛
关键词: ADAM9；实体肿瘤；研究进展；ADAM9； Solid Tumors； Research Progress
摘要: 去整合素–金属蛋白酶家族(adisintegrin and metalloproteinase, ADAMs)是一类锌依赖的跨膜糖蛋白，ADAMs家族分子具有相似的分子结构包括：结构域(单肽)末端金属域、整合素域、富含半胱氨酸的序列、膜近端上皮生长因子样序列。ADAM9在胶质瘤、黑色素瘤、前列腺癌、胰腺导管腺癌、胃癌、乳腺癌、肺癌和肝癌等实体肿瘤中均有过表达。免疫组织化学分析强调了ADAM9在实际癌细胞中的表达，并将其丰富的表达与临床病理特征联系起来，如总体生存期缩短、肿瘤分级较差、去分化、治疗耐药性和转移形成。本文综述了ADAM9在肿瘤中的研究现状，以及它在推动肿瘤进展方面的不同机制。
Abstract: A disintegrin and metalloproteinase family (ADAMs) is a zinc-dependent transmembrane glycoproteins. ADAMs family molecules have similar molecular structures including: a monopeptide terminal metal domain, an integrin domain, a cysteine-rich sequence, and a membrane proximal epithelial growth factor-like sequence. ADAM9 is over expressed in glioma, melanoma, prostate cancer, pancreatic ductal adenocarcinoma, gastric cancer, breast cancer, lung cancer, liver cancer and other solid tumors. Immunohistochemical analysis highlighted ADAM9 expression in actual cancer cells and correlated its rich expression with clinicopathological features, such as shortened overall survival, poor tumor grade, dedifferentiation, treatment resistance, and metastasis formation. In this paper, the current research status of ADAM9 in tumors and its different mechanisms in promoting tumor progression are reviewed.
文章引用：朱莉金, 罗琰, 贾清玉, 陈爱霞, 赵园园. ADAM9在实体肿瘤生物学中的相关研究进展[J]. 临床医学进展, 2020, 10(10): 2270-2280. https://doi.org/10.12677/ACM.2020.1010343

参考文献

[1] Edwards, D.R., Handsley, M.M. and Pennington, C.J. (2008) The ADAM Metalloproteinases. Molecular Aspects of Medicine, 29, 258-289. [Google Scholar] [CrossRef] [PubMed]
[2] Murphy, G. (2008) The ADAMs: Signalling Scissors in the Tumour Microenvironment. Nature Reviews Cancer, 8, 929-941. [Google Scholar] [CrossRef] [PubMed]
[3] Rocks, N., Paulissen, G., El Hour, M., Quesada, F., Crahay, C., Gueders, M., Foidart, J.M., Noel, A. and Cataldo, D. (2008) Emerging Roles of ADAM and ADAMTS Metalloproteinases in Cancer. Biochimie, 90, 369-379. [Google Scholar] [CrossRef] [PubMed]
[4] Kossmann, C.M., Annereau, M., Thomas-Schoemann, A., Nicco-Overney, C., Chereau, C., Batteux, F., Alexandre, J. and Lemare, F. (2017) ADAM9 Expression Promotes an Aggressive Lung Adenocarcinoma Phenotype. Tumor Biology, 39, Article ID: 1010428317716077. [Google Scholar] [CrossRef] [PubMed]
[5] Micocci, K.C., Martin, A.C., Montenegro Cde, F., Durante, A.C., Pouliot, N., Cominetti, M.R. and Selistre-de-Araujo, H.S. (2013) ADAM9 Silencing Inhibits Breast Tumor Cell Invasion in Vitro. Biochimie, 95, 1371-1378. [Google Scholar] [CrossRef] [PubMed]
[6] Tao, K., Qian, N., Tang, Y., Ti, Z., Song, W., Cao, D. and Dou, K. (2010) Increased Expression of a Disintegrin and Metalloprotease-9 in Hepatocellular Carcinoma: Implications for Tumor Progression and Prognosis. Japanese Journal of Clinical Oncology, 40, 645-651. [Google Scholar] [CrossRef] [PubMed]
[7] Duffy, M.J., McKiernan, E., O’Donovan, N. and McGowan, P.M. (2009) Role of ADAMs in Cancer Formation and Progression. Clinical Cancer Research, 15, 1140-1144. [Google Scholar] [CrossRef] 
[8] English, W.R., Siviter, R.J., Hansen, M. and Murphy, G. (2017) ADAM9 Is Present at Endothelial Cell-Cell Junctions and Regulates Monocyte-Endothelial Transmigration. Biochemical and Biophysical Research Communications, 493, 1057-1062. [Google Scholar] [CrossRef] [PubMed]
[9] Kim, J.M., Jeung, H.C., Rha, S.Y., Yu, E.J., Kim, T.S., Shin, Y.K., Zhang, X., Park, K.H., Park, S.W., Chung, H.C. and Powis, G. (2014) The Effect of Disintegrin-Metalloproteinase ADAM9 in Gastric Cancer Progression. Molecular Cancer Therapeutics, 13, 3074-3085. [Google Scholar] [CrossRef] 
[10] Fritzsche, F.R., Wassermann, K., Jung, M., Tolle, A., Kristiansen, I., Lein, M., Johannsen, M., Dietel, M., Jung, K. and Kristiansen, G. (2008) ADAM9 Is Highly Expressed in Renal Cell Cancer and Is Associated with Tumour Progression. BMC Cancer, 8, 179. [Google Scholar] [CrossRef] [PubMed]
[11] Li, J., Ji, Z., Qiao, C., Qi, Y. and Shi, W. (2013) Overexpression of ADAM9 Promotes Colon Cancer Cells Invasion. Journal of Investigative Surgery, 26, 127-133. [Google Scholar] [CrossRef] [PubMed]
[12] Cooper, C. (2008) Editorial Comment on: ADAM9 Expression Is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer. European Urology, 54, 1107-1108. [Google Scholar] [CrossRef] [PubMed]
[13] Fan, X., Wang, Y., Zhang, C., Liu, L., Yang, S., Wang, Y., Liu, X., Qian, Z., Fang, S., Qiao, H. and Jiang, T. (2016) ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade Gliomas. International Journal of Molecular Sciences, 17, 1276. [Google Scholar] [CrossRef] [PubMed]
[14] Shintani, Y., Higashiyama, S., Ohta, M., Hirabayashi, H., Yamamoto, S., Yoshimasu, T., Matsuda, H. and Matsuura, N. (2004) Overexpression of ADAM9 in Non-Small Cell Lung Cancer Correlates with Brain Metastasis. Cancer Research, 64, 4190-4196. [Google Scholar] [CrossRef] 
[15] Caporali, S., Amaro, A., Levati, L., Alvino, E., Lacal, P.M., Mastroeni, S., Ruffini, F., Bonmassar, L., Antonini Cappellini, G.C., Felli, N., Carè, A., Pfeffer, U. and D’Atri, S. (2019) miR-126-3p Down-Regulation Contributes to Dabrafenib Acquired Resistance in Melanoma by Up-Regulating ADAM9 and VEGF-A. Journal of Experimental & Clinical Cancer Research: CR, 38, 272. [Google Scholar] [CrossRef] [PubMed]
[16] Kohga, K., Takehara, T., Tatsumi, T., Ishida, H., Miyagi, T., Hosui, A. and Hayashi, N. (2010) Sorafenib Inhibits the Shedding of Major Histocompatibility Complex Class I-Related Chain A on Hepatocellular Carcinoma Cells by Down-Regulating a Disintegrin and Metalloproteinase 9. Hepatology (Baltimore, Md.), 51, 1264-1273. [Google Scholar] [CrossRef] [PubMed]
[17] Micocci, K.C., Moritz, M.N., Lino, R.L., Fernandes, L.R., Lima, A.G., Figueiredo, C.C., Morandi, V. and Selistre-de-Araujo, H.S. (2016) ADAM9 Silencing Inhibits Breast Tumor Cells Transmigration through Blood and Lymphatic Endothelial Cells. Biochimie, 128-129, 174-182. [Google Scholar] [CrossRef] [PubMed]
[18] Zigrino, P., Nischt, R. and Mauch, C. (2011) The Disintegrin-Like and Cysteine-Rich Domains of ADAM-9 Mediate Interactions between Melanoma Cells and Fibroblasts. The Journal of Biological Chemistry, 286, 6801-6807. [Google Scholar] [CrossRef] 
[19] Mygind, K.J., Schwarz, J., Sahgal, P., Ivaska, J. and Kveiborg, M. (2018) Loss of ADAM9 Expression Impairs beta1 Integrin Endocytosis, Focal Adhesion Formation and Cancer Cell Migration. Journal of Cell Science, 131, jcs205393. [Google Scholar] [CrossRef] [PubMed]
[20] Tannapfel, A., Anhalt, K., Hausermann, P., Sommerer, F., Benicke, M., Uhlmann, D., Witzigmann, H., Hauss, J. and Wittekind, C. (2003) Identification of Novel Proteins Associated with Hepatocellular Carcinomas Using Protein Microarrays. The Journal of Pathology, 201, 238-249. [Google Scholar] [CrossRef] [PubMed]
[21] Arai, J., Goto, K., Stephanou, A., Tanoue, Y., Ito, S., Muroyama, R., Matsubara, Y., Nakagawa, R., Morimoto, S., Kaise, Y., Lim, L.A., Yoshida, H. and Kato, N. (2018) Predominance of Regorafenib over Sorafenib: Restoration of Membrane-Bound MICA in Hepatocellular Carcinoma Cells. Journal of Gastroenterology and Hepatology, 33, 1075-1081. [Google Scholar] [CrossRef] [PubMed]
[22] Oh, S., Park, Y., Lee, H.J., Lee, J., Lee, S.H., Baek, Y.S., Chun, S.K., Lee, S.M., Kim, M., Chon, Y.E., Ha, Y., Cho, Y., Kim, G.J., Hwang, S.G. and Kwack, K. (2020) A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker during Hepatocellular Carcinoma Immunotherapy. Cancers, 12, 745. [Google Scholar] [CrossRef] [PubMed]
[23] Dong, Y., Wu, Z., He, M., Chen, Y., Chen, Y., Shen, X., Zhao, X., Zhang, L., Yuan, B. and Zeng, Z. (2018) ADAM9 Mediates the Interleukin-6-Induced Epithelial-Mesenchymal Transition and Metastasis through ROS Production in Hepatoma Cells. Cancer Letters, 421, 1-14. [Google Scholar] [CrossRef] [PubMed]
[24] Li, S.-Q., et al. (2015) The Protective Roles of IL-6 Trans-Signaling Regulated by ADAM9 on the Liver in Carbon Tetrachloride-Induced Liver Injury in Mice. Journal of Biochemical and Molecular Toxicology, 29, 340-348. [Google Scholar] [CrossRef] [PubMed]
[25] Wan, D., Shen, S., Fu, S., Preston, B., Brandon, C., He, S., Shen, C., Wu, J., Wang, S., Xie, W., Chen, B., Liya, A., Guo, Y., Zheng, D., Zhi, Q. and Peng, B. (2016) miR-203 Suppresses the Proliferation and Metastasis of Hepatocellular Carcinoma by Targeting Oncogene ADAM9 and Oncogenic Long Non-Coding RNA HULC. Anti-Cancer Agents in Medicinal Chemistry, 16, 414-423. [Google Scholar] [CrossRef] [PubMed]
[26] Hu, D., Shen, D., Zhang, M., Jiang, N., Sun, F., Yuan, S. and Wan, K. (2017) MiR-488 Suppresses Cell Proliferation and Invasion by Targeting ADAM9 and lncRNA HULC in Hepatocellular Carcinoma. American Journal of Cancer Research, 7, 2070-2080.
[27] Xiang, L.Y., Ou, H.H., Liu, X.C., Chen, Z.J., Li, X.H., Huang, Y. and Yang, D.H. (2017) Loss of Tumor Suppressor miR-126 Contributes to the Development of Hepatitis B Virus-Related Hepatocellular Carcinoma Metastasis through the Upregulation of ADAM9. Tumor Biology, 39, 1010428317709128. [Google Scholar] [CrossRef] [PubMed]
[28] Fritzsche, F.R., Jung, M., Tölle, A., Wild, P., Hartmann, A., Wassermann, K., Rabien, A., Lein, M., Dietel, M., Pilarsky, C., Calvano, D., Grützmann, R., Jung, K. and Kristiansen, G. (2008) ADAM9 Expression Is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer. European Urology, 54, 1097-1106. [Google Scholar] [CrossRef] [PubMed]
[29] Sung, S.Y., Kubo, H., Shigemura, K., Arnold, R.S., Logani, S., Wang, R., Konaka, H., Nakagawa, M., Mousses, S., Amin, M., Anderson, C., Johnstone, P., Petros, J.A., Marshall, F.F., Zhau, H.E. and Chung, L.W. (2006) Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells. Cancer Research, 66, 9519-9526. [Google Scholar] [CrossRef] 
[30] Josson, S., et al. (2011) Inhibition of ADAM9 Expression Induces Epithelial Phenotypic Alterations and Sensitizes Human Prostate Cancer Cells to Radiation and Chemotherapy. Prostate, 71, 232-240. [Google Scholar] [CrossRef] [PubMed]
[31] Liu, C.M., et al. (2013) In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression. PLoS ONE, 8, e53795. [Google Scholar] [CrossRef] [PubMed]
[32] Hua, Y., Liang, C., Miao, C., Wang, S., Su, S., Shao, P., Liu, B., Bao, M., Zhu, J., Xu, A., Zhang, J., Li, J. and Wang, Z. (2018) MicroRNA-126 Inhibits Proliferation and Metastasis in Prostate Cancer via Regulation of ADAM9. Oncology Letters, 15, 9051-9060. [Google Scholar] [CrossRef] [PubMed]
[33] Carl-McGrath, S., Lendeckel, U., Ebert, M., Roessner, A. and Röcken, C. (2005) The Disintegrin-Metalloproteinases ADAM9, ADAM12, and ADAM15 Are Upregulated in Gastric Cancer. International Journal of Oncology, 26, 17-24. [Google Scholar] [CrossRef] 
[34] Wang, J., Zhou, Y., Fei, X., Chen, X., Yan, J., Liu, B. and Zhu, Z. (2017) ADAM9 Functions as a Promoter of Gastric Cancer Growth Which Is Negatively and Post-Transcriptionally Regulated by miR-126. Oncology Reports, 37, 2033-2040. [Google Scholar] [CrossRef] [PubMed]
[35] Hamada, S., Satoh, K., Fujibuchi, W., Hirota, M., Kanno, A., Unno, J., Masamune, A., Kikuta, K., Kume, K. and Shimosegawa, T. (2012) MiR-126 Acts as a Tumor Suppressor in Pancreatic Cancer Cells via the Regulation of ADAM9. Molecular Cancer Research: MCR, 10, 3-10. [Google Scholar] [CrossRef] 
[36] Wang, S., Wang, X., Guo, Q., Wang, G., Han, X., Li, X., Shi, Z.W. and He, W. (2016) MicroRNA-126 Overexpression Inhibits Proliferation and Invasion in Osteosarcoma Cells. Technology in Cancer Research & Treatment, 15, Np49-59. [Google Scholar] [CrossRef] [PubMed]
[37] Liu, Q., et al. (2018) MiR-129-5p Functions as a Tumor Suppressor in Gastric Cancer Progression through Targeting ADAM9. Biomedicine & Pharmacotherapy, 105, 420-427. [Google Scholar] [CrossRef] [PubMed]
[38] Grützmann, R., et al. (2004) ADAM9 Expression in Pancreatic Cancer Is Associated with Tumour Type and Is a Prognostic Factor in Ductal Adenocarcinoma. British Journal of Cancer, 90, 1053-1058. [Google Scholar] [CrossRef] [PubMed]
[39] Yamada, D., et al. (2007) Increased Expression of ADAM9 and ADAM15 mRNA in Pancreatic Cancer. Anticancer Research, 27, 793-799.
[40] Xing, C., Ye, H., Wang, W., Sun, M., Zhang, J., Zhao, Z. and Jiang, G. (2019) Circular RNA ADAM9 Facilitates the Malignant Behaviours of Pancreatic Cancer by Sponging miR-217 and Upregulating PRSS3 Expression. Artificial Cells, Nanomedicine, and Biotechnology, 47, 3920-3928. [Google Scholar] [CrossRef] [PubMed]
[41] Wu, D.M., et al. (2019) Bone Marrow Mesenchymal Stem Cell-Derived Exosomal MicroRNA-126-3p Inhibits Pancreatic Cancer Development by Targeting ADAM9. Molecular Therapy—Nucleic Acids, 16, 229-245. [Google Scholar] [CrossRef] [PubMed]
[42] Hamada, S., et al. (2012) MiR-126 Acts as a Tumor Suppressor in Pancreatic Cancer Cells via the Regulation of ADAM9. Molecular Cancer Research, 10, 3-10. [Google Scholar] [CrossRef] 
[43] Zhang, J., Qi, J., Chen, N., Fu, W., Zhou, B. and He, A. (2013) High Expression of a Disintegrin and Metalloproteinase-9 Predicts a Shortened Survival Time in Completely Resected Stage I Non-Small Cell Lung Cancer. Oncology Letters, 5, 1461-1466. [Google Scholar] [CrossRef] [PubMed]
[44] Zhang, J., Chen, N., Qi, J., Zhou, B. and Qiu, X. (2014) HDGF and ADAM9 Are Novel Molecular Staging Biomarkers, Prognostic Biomarkers and Predictive Biomarkers for Adjuvant Chemotherapy in Surgically Resected Stage I Non-Small Cell Lung Cancer. Journal of Cancer Research and Clinical Oncology, 140, 1441-1449. [Google Scholar] [CrossRef] [PubMed]
[45] Shintani, Y., et al. (2004) Overexpression of ADAM9 in Non-Small Cell Lung Cancer Correlates with Brain Metastasis. Cancer Research, 64, 4190-4196. [Google Scholar] [CrossRef] 
[46] Wan, J., Hao, L., Zheng, X. and Li, Z. (2019) Circular RNA circ_0020123 Promotes Non-Small Cell Lung Cancer Progression by Acting as a ceRNA for miR-488-3p to Regulate ADAM9 Expression. Biochemical and Biophysical Research Communications, 515, 303-309. [Google Scholar] [CrossRef] [PubMed]
[47] Wang, F.F., et al. (2016) microRNA-590 Suppresses the Tumorigenesis and Invasiveness of Non-Small Cell Lung Cancer Cells by Targeting ADAM9. Molecular and Cellular Biochemistry, 423, 29-37. [Google Scholar] [CrossRef] [PubMed]
[48] Chang, J.H., et al. (2017) Quercetin Suppresses the Metastatic Ability of Lung Cancer through Inhibiting Snail-Dependent Akt Activation and Snail-Independent ADAM9 Expression Pathways. Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, 1864, 1746-1758. [Google Scholar] [CrossRef] [PubMed]
[49] Chang, L., Gong, F. and Cui, Y. (2015) RNAi-Mediated A Disintegrin and Metalloproteinase 9 Gene Silencing Inhibits the Tumor Growth of Non-Small Lung Cancer in Vitro and in Vivo. Molecular Medicine Reports, 12, 1197-1204. [Google Scholar] [CrossRef] [PubMed]
[50] Chang, L., Gong, F., Cai, H., Li, Z. and Cui, Y. (2016) Combined RNAi Targeting Human Stat3 and ADAM9 as Gene Therapy for Non-Small Cell Lung Cancer. Oncology Letters, 11, 1242-1250. [Google Scholar] [CrossRef] [PubMed]
[51] Lin, C.Y., Chen, H.J., Huang, C.C., Lai, L.C., Lu, T.P., Tseng, G.C., Kuo, T.T., Kuok, Q.Y., Hsu, J.L., Sung, S.Y., Hung, M.C. and Sher, Y.P. (2014) ADAM9 Promotes Lung Cancer Metastases to Brain by a Plasminogen Activator-Based Pathway. Cancer Research, 74, 5229-5243. [Google Scholar] [CrossRef] 
[52] Chiu, K.L., Kuo, T.T., Kuok, Q.Y., Lin, Y.S., Hua, C.H., Lin, C.Y., Su, P.Y., Lai, L.C. and Sher, Y.P. (2015) ADAM9 Enhances CDCP1 Protein Expression by Suppressing miR-218 for Lung Tumor Metastasis. Scientific Reports, 5, Article No. 16426. [Google Scholar] [CrossRef] [PubMed]
[53] Lin, C.Y., Cho, C.F., Bai, S.T., Liu, J.P., Kuo, T.T., Wang, L.J., Lin, Y.S., Lin, C.C., Lai, L.C., Lu, T.P., Hsieh, C.Y., Chu, C.N., Cheng, D.C. and Sher, Y.P. (2017) ADAM9 Promotes Lung Cancer Progression through Vascular Remodeling by VEGFA, ANGPT2, and PLAT. Scientific Reports, 7, Article No. 15108. [Google Scholar] [CrossRef] [PubMed]
[54] O’Shea, C., McKie, N., Buggy, Y., Duggan, C., Hill, A.D., McDermott, E., O’Higgins, N. and Duffy, M.J. (2003) Expression of ADAM-9 mRNA and Protein in Human Breast Cancer. International Journal of Cancer, 105, 754-761. [Google Scholar] [CrossRef] [PubMed]
[55] Qin, C., Zhao, Y., Gong, C. and Yang, Z. (2017) MicroRNA-154/ADAM9 Axis Inhibits the Proliferation, Migration and Invasion of Breast Cancer Cells. Oncology Letters, 14, 6969-6975. [Google Scholar] [CrossRef] [PubMed]
[56] Moelans, C.B., de Weger, R.A., Monsuur, H.N., Vijzelaar, R. and van Diest, P.J. (2010) Molecular Profiling of Invasive Breast Cancer by Multiplex Ligation-Dependent Probe Amplification-Based Copy Number Analysis of Tumor Suppressor and Oncogenes. Modern Pathology, 23, 1029-1039. [Google Scholar] [CrossRef] [PubMed]
[57] Fry, J.L. and Toker, A. (2010) Secreted and Membrane-Bound Isoforms of Protease ADAM9 Have Opposing Effects on Breast Cancer Cell Migration. Cancer Research, 70, 8187-8198. [Google Scholar] [CrossRef] 
[58] Mazzocca, A., Coppari, R., De Franco, R., Cho, J.Y., Libermann, T.A., Pinzani, M. and Toker, A. (2005) A Secreted Form of ADAM9 Promotes Carcinoma Invasion through Tumor-Stromal Interactions. Cancer Research, 65, 4728-4738. [Google Scholar] [CrossRef] 
[59] Davis, S.L., Eckhardt, S.G., Tentler, J.J. and Diamond, J.R. (2014) Triple-Negative Breast Cancer: Bridging the Gap from Cancer Genomics to Predictive Biomarkers. Therapeutic Advances in Medical Oncology, 6, 88-100. [Google Scholar] [CrossRef] [PubMed]
[60] Carey, L.A., Rugo, H.S., Marcom, P.K., Mayer, E.L., Esteva, F.J., Ma, C.X., Liu, M.C., Storniolo, A.M., Rimawi, M.F., Forero-Torres, A., Wolff, A.C., Hobday, T.J., Ivanova, A., Chiu, W.K., Ferraro, M., Burrows, E., Bernard, P.S., Hoadley, K.A., Perou, C.M. and Winer, E.P. (2012) TBCRC 001: Randomized Phase II Study of Cetuximab in Combination with Carboplatin in Stage IV Triple-Negative Breast Cancer. Journal of Clinical Oncology, 30, 2615-2623. [Google Scholar] [CrossRef] 
[61] Nakai, K., Hung, M.C. and Yamaguchi, H. (2016) A Perspective on Anti-EGFR Therapies Targeting Triple-Negative Breast Cancer. American Journal of Cancer Research, 6, 1609-1623.
[62] Costa, R., Shah, A.N., Santa-Maria, C.A., Cruz, M.R., Mahalingam, D., Carneiro, B.A., Chae, Y.K., Cristofanilli, M., Gradishar, W.J. and Giles, F.J. (2017) Targeting Epidermal Growth Factor Receptor in Triple Negative Breast Cancer: New Discoveries and Practical Insights for Drug Development. Cancer Treatment Reviews, 53, 111-119. [Google Scholar] [CrossRef] [PubMed]
[63] Wang, J.J., Zou, J.X., Wang, H., Duan, Z.J., Wang, H.B., Chen, P., Liu, P.Q., Xu, J.Z. and Chen, H.W. (2019) Histone Methyltransferase NSD2 Mediates the Survival and Invasion of Triple-Negative Breast Cancer Cells via Stimulating ADAM9-EGFR-AKT Signaling. Acta Pharmacologica Sinica, 40, 1067-1075. [Google Scholar] [CrossRef] [PubMed]
[64] Huang, C.F., Yang, S.F., Chiou, H.L., Hsu, W.H., Hsu, J.C., Liu, C.J. and Hsieh, Y.H. (2018) Licochalcone A Inhibits the Invasive Potential of Human Glioma Cells by Targeting the MEK/ERK and ADAM9 Signaling Pathways. Food & Function, 9, 6196-6204. [Google Scholar] [CrossRef] 
[65] Lei, D., et al. (2018) Galangin Increases ERK1/2 Phosphorylation to Decrease ADAM9 Expression and Prevents Invasion in A172 Glioma Cells. Molecular Medicine Reports, 17, 667-673. [Google Scholar] [CrossRef] [PubMed]
[66] Brösicke, N., van Landeghem, F.K., Scheffler, B. and Faissner, A. (2013) Tenascin-C Is Expressed by Human Glioma in Vivo and Shows a Strong Association with Tumor Blood Vessels. Cell and Tissue Research, 354, 409-430. [Google Scholar] [CrossRef] [PubMed]
[67] Sarkar, S., Zemp, F.J., Senger, D., Robbins, S.M. and Yong, V.W. (2015) ADAM-9 Is a Novel Mediator of Tenascin-C-Stimulated Invasiveness of Brain Tumor-Initiating Cells. Neuro-Oncology, 17, 1095-1105. [Google Scholar] [CrossRef] [PubMed]
[68] Liu, X., Wang, S., Yuan, A., Yuan, X. and Liu, B. (2016) MicroRNA-140 Represses Glioma Growth and Metastasis by Directly Targeting ADAM9. Oncology Reports, 36, 2329-2338. [Google Scholar] [CrossRef] [PubMed]
[69] Formolo, C.A., Williams, R., Gordish-Dressman, H., MacDonald, T.J., Lee, N.H. and Hathout, Y. (2011) Secretome Signature of Invasive Glioblastoma Multiforme. Journal of Proteome Research, 10, 3149-3159. [Google Scholar] [CrossRef] [PubMed]
[70] Zigrino, P., et al. (2005) Adam-9 Expression and Regulation in Human Skin Melanoma and Melanoma Cell Lines. International Journal of Cancer, 116, 853-859. [Google Scholar] [CrossRef] [PubMed]
[71] Mohd Isa, S.A., Md Salleh, M.S., Ismail, M.P. and Hairon, S.M. (2019) ADAM9 Expression in Uterine Cervical Cancer and Its Associated Factors. Asian Pacific Journal of Cancer Prevention, 20, 1081-1087. [Google Scholar] [CrossRef] 
[72] Tanasubsinn, P., Aung, W.P.P., Pata, S., Laopajon, W., Makeudom, A., Sastraruji, T., Kasinrerk, W. and Krisanaprakornkit, S. (2018) Overexpression of ADAM9 in Oral Squamous Cell Carcinoma. Oncology Letters, 15, 495-502. [Google Scholar] [CrossRef] [PubMed]
[73] Hsieh, M.H., Tsai, J.P., Yang, S.F., Chiou, H.L., Lin, C.L., Hsieh, Y.H. and Chang, H.R. (2019) Fisetin Suppresses the Proliferation and Metastasis of Renal Cell Carcinoma through Upregulation of MEK/ERK-Targeting CTSS and ADAM9. Cells, 8, 948-963. [Google Scholar] [CrossRef] [PubMed]
[74] Yang, X., Cui, Y., Yang, F., Sun, C. and Gao, X. (2017) MicroRNA302a Suppresses Cell Proliferation, Migration and Invasion in Osteosarcoma by Targeting ADAM9. Molecular Medicine Reports, 16, 3565-3572. [Google Scholar] [CrossRef] [PubMed]

为你推荐